Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Hypoxic Respiratory Failure in Preterm Infants
NCT00922532Phase 3Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- Oct 2011
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial of nitric oxide in hypoxic respiratory failure and pulmonary hypertension (PH) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Change in oxygenation (Arterial Blood Gases) at 1 hour. Planned start Nov 2009; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
hypoxic respiratory failurepulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00922532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922532.